Generic selectors
Exact matches only
Search in title
Search in content
Generic selectors
Exact matches only
Search in title
Search in content

Remdesivir (thought to treat COVID-19) is out

newsflight november 23

Markets

Nikkei 225

25,527.37

▼ -106.97 / -0.42%

SSE Composite

3,377.73

▲ +14.64 / +0.44%

Bovespa

106,042.48

▼ -627.42 / -0.59%

Straits Times

2,813.01

▲ +36.01 / +1.30%

BMV IPC

41,905.06

▲ +36.24 / +0.09%

Dow Jones

29,263.48

▼ -219.75 / -0.75%

DAX 30

13,137.25

▲ +51.09 / +0.39%

BSE SENSEX

43,882.25

▲ +282.29 / +0.65%

FTSE 100

6,351.45

▲ +17.10 / +0.27%

JSE Top 40

51,915.40

▼ -62.51 / -0.12%

Market News

  • Nikkei 225: Japan’s Nikkei index started the day down and never got out of the red, eventually closing down 0.42%
  • CAC 40: Up 11.49% over this past month, France’s CAC 40 index closed Friday up just 0.39%.
  • IPSA: Following a year of volatility, Chile’s IPSA index is up 10.39% this past month, but 15.29% down over the last year.

Last Week’s Highlights

Remdesivir Officially Out

Remember a few months back when Gilead’s medicine remdesivir appeared to be showing positive results in early stages of experimental COVID-19 treatments? Well, the WHO has officially announced that its use doesn’t appear to help much at all, in fact. For this very reason, the WHO has concluded that the drug never be used to treat symptoms of COVID-19.

New AIDS Medication Gives Patients Their Time Back

While scientific research and social awareness of AIDS has certainly come a long way in the last several decades, much lies ahead to improve care and medical treatment. Medications for prevention and treatment have continued to improve, but many require daily consumption, causing patient fatigue. However, a new path towards medicines with the power to last longer appears to now be a possibility with Cabenuva, a once-a-month injection.

Coming Up This Week

More and More Pharmaceuticals Announce Vaccines

Major players in big pharma have begun to announce the results of the third phase of their clinical trials for a SARS-CoV-2 vaccine. In the United States, the first companies to apply for FDA approval are Pfizer and BioNTech, who claim 95% effectiveness. As well, expecting full results in December is Oxford-Astrazeneca. In China as well there appear to be companies touting success over 1 million patients.

Is the Paris Agreement Back on the US?

President-elect Joe Biden had promised to rejoin the Paris Agreement on environmental regulation and preventative action upon entering the White House in January. And while this sounds like good news for Mother Earth, the reality of the Paris Agreement is that some countries do not appear on track to reach the preset goals.


More Things to Sip On…

More than 100,000 deaths officially in Mexico have been reported.

After a clear loss in the United States’ presidential election, Donald Trump continues to argue for baseless claims of election fraud.

Thinking about fibbing about your whereabouts? Millions could be at risk as a result.


Academy

5 Investment Tips To Become A Smart Investor

simple investment tips

“Why don’t you invest? Or why do your friends not invest? Many millennials report mistrust of the market, lack of know-how, insufficient funds, and student debt as barriers that prevent them from investing.”

Learn more »

6 Steps to set your Personal Financial Goals

financial goals

“No matter what stage of life you currently find yourself in, we’re pretty sure that you’ve given some thought about both your short- and long-term personal financial goals.”

Learn more »

20 Side Hustle Ideas to Boost Your Income

side hustle

“A side gig, moonlighting, or, as the kids call it these days, a side hustle is an excellent way to diversify your income, make a hobby profitable, and even build your confidence.” 

Learn more »

“During recession greed dies, frugality survives.”
– Amit Kalantri –


Disclaimer
Visit our Disclosures section for additional information. All market information provided was collected in the afternoon of November 20, 2020. The purpose of NewsFlight is to summarize and make accessible information on a variety of topics within the world of investing and personal finance, and thus cannot be considered formal research or reports. All sources utilized to compile the NewsFlight newsletter are considered trustworthy by the FlexInvest team. FlexInvest is not affiliated with and does not receive remuneration from the news sources used to compile NewsFlight. As well, any images or logos incorporated into the NewsFlight newsletter are not necessarily property of FlexInvest and may solely be included to provide context for the news covered. NewsFlight should not be taken as advice to sell or buy securities or to make any investment. When investing in securities or other financial products, there is always the potential to lose money or asset value. FlexInvest recommends that its users consider their investment objectives and risks before investing. Additionally, any projections or analysis made by authors of NewsFlight cannot be considered as a promise of future trends or returns. Opinions expressed in News Flight are not representative of FlexInvest Inc.

MARKET NEWS

More Things to Sip On…

FlexACADEMY

Disclaimer
All information provided was collected up to the last business day of the previous week of the release of this NewsFlight. The purpose of NewsFlight is to summarize and make accessible information on a variety of topics within the world of investing and personal finance, and thus cannot be considered formal research or reports. All sources utilized to compile the NewsFlight newsletter are considered trustworthy by the FlexInvest team. FlexInvest is not affiliated with and does not receive remuneration from the news sources used to compile NewsFlight. As well, any images or logos incorporated into the NewsFlight newsletter are not necessarily property of FlexInvest and may solely be included to provide context for the news covered. NewsFlight should not be taken as advice to sell or buy securities or to make any investment. When investing in securities or other financial products, there is always the potential to lose money or asset value. FlexInvest recommends that its users consider their investment objectives and risks before investing. Additionally, any projections or analysis made by authors of NewsFlight cannot be considered as a promise of future trends or returns. Opinions expressed in NewsFlight are not representative of FlexInvest.